

CSD/BSE&NSE/2024-25  
July 13, 2024

**To**  
**The Manager**  
**Department of Corporate Services**  
**BSE Limited**  
**25th Floor, P. J. Towers,**  
**Dalal Street, Mumbai - 400 001**

**To**  
**The Manager**  
**Listing Department**  
**National Stock Exchange of India Limited**  
**Exchange Plaza, Bandra Kurla Complex**  
**Bandra (E), Mumbai – 400 051**

**Scrip Code: 543064**

**Scrip Symbol: SUVENPHAR**

Dear Sir/Madam,

**Sub: Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

.....

We are pleased to inform you that the United States Food & Drug Administration (US FDA) has completed the surveillance inspection of Casper Pharma Private Limited in Hyderabad (WOS of our company). The inspection took place from July 8, 2024, to July 12, 2024. Following the inspection, we have been issued a Form 483 with two observations, which are procedural in nature. We are committed to addressing these observations within the stipulated timeline.

This is for your information and record.

Thanking you,  
Yours faithfully,  
For **Suven Pharmaceuticals Limited**

**K. Hanumantha Rao**  
Company Secretary

## **Suven Pharmaceuticals Limited**

**Registered Office:** # 215 Atrium, C Wing, 8th Floor,  
819-821, Andheri Kurla Road, Chakala, Andheri East,  
Chakala Midc, Mumbai- 400093, Maharashtra, India  
Tel: 91 22 61539999

**Corporate Office:** # 202, A-Wing, Galaxy Towers,  
Plot No.1, Hyderabad Knowledge City, TSIC,  
Raidurg, Hyderabad - 500081 Telangana, India  
Tel: 91 40 2354 9414 / 3311

Email: [info@suvenpharm.com](mailto:info@suvenpharm.com) | Website: [www.suvenpharm.com](http://www.suvenpharm.com) | CIN: L24299MH2018PLC422236